Agile Therapeutics Inc Stock: price and insider trades · United States

Agile Therapeutics Inc. (ticker AGRX) was a U.S.-based women’s healthcare company focused primarily on contraception, with its core franchise built around Twirla®, a once-weekly prescription contraceptive patch. The company was incorporated in Delaware on December 22, 1997, and historically operated from Princeton, New Jersey, United States. In its SEC filings, Agile described itself as a women’s healthcare company dedicated to addressing unmet needs in women’s health, with a particular emphasis on a non-daily hormonal contraceptive option. The business model combined clinical development, regulatory execution, commercialization, and payer-access work around a single lead product. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1261249/000155837024004262/agrx-20231231x10k.htm))

Twirla was Agile’s first and only approved product. The patch received FDA approval in February 2020 and was launched commercially in December 2020. Agile’s strategy centered on improving reimbursement, widening access through pharmacies and telehealth channels, and targeting obstetrician-gynecologists and women of reproductive age in the United States. The company said it focused its promotional effort on select high-potential U.S. states and used a lean sales-and-marketing footprint supported by third-party commercial partners. That made Agile a highly concentrated commercial story: upside depended on adoption of one product, while downside risk reflected payer pressure, competition, and the operational challenges typical of small-cap specialty pharma companies. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1261249/000155837024004262/agrx-20231231x10k.htm))